HSPB1 and neoplasm: Exogenous administration of HSPB1 inhibited the migration of HOS tumor cells through HUVECs, while HSPB1-neutralizing antibodies that trapped soluble HSPB1 increased tumor cell transendothelial migration (Figure S1A and B in File S1).